).Givenourfindingthat nuclearlocalizationoftheFETproteinmutantscanberestoredbyAdOxtreatment (Fig.2) and thefactthatallFETproteinsareargininemethylatedwithintheRGGdomainnexttothePY-NLS (Belyanskayaetal.,2001; Duetal.,2011; Hungetal.,2009; Jobertetal.,2009; Leeand Bedford,2002; Ongetal.,2004; Pahlichetal.,2005; Rappsilberetal.,2003) thank you for your interest in our manuscript "Arginine methylation next to the PY-NLS modulates Transportin-mediated nuclear import of FUS". We appreciate your helpful comments and believe that we can fully address all of the concerns that you and the reviewers have raised.
As mentioned before, we have generated novel monoclonal antibodies specific for methylated FUS. This unique tool will allow us to examine the methylation status of FUS in cells and human post mortem brains. By now, we have thoroughly characterized the antibodies and can show that they are specific for methylated FUS and work in immunoblot and immunocytochemistry ( Fig. R1A and B) . Moreover, we can show that ALS-associated FUS mutants are indeed methylated ( (Fig. R1C ), supporting our hypothesis that arginine methylation might be involved in the pathogenesis of ALS with FUS mutations (last section of our discussion). These data are ready to be included in a revised manuscript. We are currently also testing if our antibodies work on paraffin sections and are planning to use them for IHC on post mortem brains of FTLD/ALS-FUS patients. If they do, we will investigate if cytosolic deposits in FTLD/ALS-FUS brains contain methylated FUS. In addition to the potential pathological impact, our data also provide novel insights into the function of arginine methylation in nuclear transport of FET proteins, as pointed out by the reviewers. First of all, our data identify the RGG domain of FUS as a previously unknown TRN binding epitope (epitope 4 in Fig. 8 ) and suggest a novel model of TRN-substrate recognition, where the previously described epitopes 1-3 anchor the substrate in the TRN binding pocket and the adjacent RGG repeats (epitope 4) stabilize the interaction. Second, we find a small, but statistically significant effect of methylation inhibition on nuclear import of wild-type FUS (p<0.05; unpaired two-tailed t-test). We thus suggest that arginine methylation may fine-tune nucleocytoplasmic localization of FUS, which is thought to have essential functions both in the nucleus and the cytoplasm and this most likely requires an accurately controlled nuclear import mechanism.
To address the additional issues raised by the reviewers, we have completed or started the following experiments:
Referee #1: 1-We examined some of the TAF15 mutations described by Couthouis et al., PNAS 2011. However, we could not reproduce the cytoplasmic mislocalization reported for these mutants and therefore had to introduce a point mutation in the NLS of TAF15 in order to demonstrate an effect of AdOx on nuclear import of TAF15. 2-As described above, we will use our novel meFUS-specific antibodies to show that ALS-associated FUS mutants are indeed methylated.
Referee #2: 1-As suggested by the reviewer, we will revise our definition of the PY-NLS and will discuss the interesting questions brought up by the reviewer. 2-We will present a selection of the ITC binding curves in the supplement and will put all dissociation constants in a table (Fig. R2) . Moreover, we measured binding of two new peptides (504-526-WT and P525L) to TRN. This demonstrates that the WT peptide binds to TRN with much higher affinity than the mutant and shows that addition of the RGG3 region strongly enhances binding to TRN (Fig. R2) . 3-We will analyze the RGG3-TRN interaction for sensitivity to Ran-GTP.
Referee #3: 1-We will include a statement that all results shown are representative of several experiments. 2-We will show statistics demonstrating that the small differences in nuclear localization of FUS-WT with and without AdOx did not occur by chance, but are statistically significant. 3-We will use our novel meFUS-specific antibodies to provide evidence that ALS-associated FUS mutants are methylated. Thus we believe that we can address all questions raised by the reviewers and demonstrate important mechanistic insights into the arginine methylation-dependent regulation of nuclear import of FUS and its potential role in disease.
1st Editorial Decision 23 May 2012
Thank you for sending me your detailed point-by-point response I have now had a chance to take a look at it.
I find that the inclusion of the data using the developed monoclonal antibodies against methylated FUS will clearly strengthen the paper and add more support for that arginine methylation is involved in pathogenesis. Adding data using the Abs on FTLD/ALS-FUS patient samples would also significantly add to the paper. Given this I would like to ask you to submit a suitably revised manuscript that includes the data as indicated in your point-point response.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html I thank you for the opportunity to consider your work for publication. I look forward to seeing your revision. Couthouis et al., 2011, PNAS and Couthouis et al, 2012, HMG) . We followed the reviewer's advice and examined some of the TAF15 mutations described by Couthouis et al., PNAS 2011 (M368T, D386N, G391E and G473E) . However, we did not observe the cytoplasmic accumulation referred to by the reviewer and therefore had to use a TAF15 mutant with a PY-NLS mutation (P591L) in order to demonstrate the effect of AdOx on nuclear import of TAF15. The reviewer criticized that the pathological implications of our findings have only been addressed in the discussion. We therefore generated monoclonal antibodies specific to methylated FUS (new Fig. 8 ) and examined the methylation status of FUS in our cellular models and post mortem tissue of ALS-FUS and FTLD-FUS patients. Using these unique tools, we can now show that ALS-associated FUS mutants are indeed methylated and that stress granules, the potential precursors of pathological FUS inclusions (Dormann et al, EMBO J 2010; Bosco et al, Hum Mol Gen 2010 , Gal et al, Neurobiol Aging 2010 , contain methylated FUS as well (new Fig. 8 ). More importantly, we find that FUS inclusions in ALS-FUS patients are strongly co-labeled with our meFUS-specific antibodies (new Fig. 9A ), supporting our hypothesis that arginine methylation is required for the pathological mislocalization of ALS-associated FUS mutants.
2-The potential pathological implications of these proteins has only been addressed in the
Interestingly, we found that in contrast to ALS-FUS, FUS inclusions in FTLD-FUS patients are unmethylated (new Fig. 9B ), suggesting that hypomethylation of FUS and the related EWS and TAF15 proteins (FET proteins) may be responsible for the co-deposition of FET proteins and TRN in pathological inclusions. Even though we agree with the reviewer that localization of FUS, TAF, and EWS is only very slightly affected by AdOx treatment ( Fig. 1 and 2 ), our in vitro pulldown experiments and ITC data (Fig. 7C) clearly demonstrate that binding of FUS-WT to TRN is affected by arginine methylation. Even though differences in TRN binding affinity of methylated versus unmethylated FUS-WT may be small, it seems possible that over long periods of time, a slight increase in FET-TRN binding may lead to a co-deposition of FET proteins and TRN in this lateonset neurodegenerative disease. This may be analogous to the very subtle changes in amyloid ß-peptide metabolism in sporadic Alzheimer cases as compared to the dramatic differences observed in familial cases.
Referee #2

This reviewer finds our paper "interesting and technically largely convincing. Its importance is slightly diminished by the fact that Fronz et al. (cited in the manuscript) already reported a weakening of the interaction between the protein PABPN1 and transportin by arginine methylation of the former. Thus, the claim that 'a novel concept' is revealed (abstract and first sentence of discussion) should be deleted. Nevertheless, the current manuscript goes significantly beyond the Fronz paper by showing effects on arginine methylation in cells, whereas the earlier paper was limited to in vitro binding and nuclear import assays. The possible role of arginine methylation in human genetic diseases, ALS and FTLD, is also interesting.
As requested by the reviewer, we deleted the claim of 'a novel concept' and now only state that a "novel TRN binding epitope" is revealed. 
the NLS. In this context, arginine methylation of PABPN1 occurs both within the known consensus sequences of the PY-NLS and in more upstream regions. As the effect of arginine methylation on transportin binding is the same as in FUS, it appears artificial to make a distinction between PY-NLS and 'outside' sequences affecting transportin binding.
We have previously shown that an even shorter sequence of FUS (residues 514-526) is necessary and sufficient for nuclear import of FUS (Dormann et al., EMBO J 2010) and a recent Xray crystallography study by Chook and colleagues showed that epitopes 1-3 of TRN are located in residues 508-526 (Zhang et al, PNAS 2012). Therefore, we think that it is correct to designate the residues C-terminal of the RGG3 repeat region (506-526) as PY-NLS harboring epitopes 1-3 (see schematic diagrams in Fig. 1A and 10A) .
We show for the first time that the RGG repeat domain of FUS can be considered a new TRN binding epitope (epitope 4 in Fig. 10A ). We agree with the reviewer that in the future this domain should be considered part of the PY-NLS of FUS. However, in our manuscript we still make the distinction between PY-NLS (epitopes 1-3, light red) and RGG repeat region (epitope 4, light green) for historic reasons and better comprehension. (unmethylated versus methylated:172 versus higher than 200 microM; p. 12) 
2-At least a selection of ITC
. Is this difference really bigger than that for the WT peptide (2.8 versus 7.8)?
As suggested by the reviewer, we now show the experimental ITC curves for FUS454-526 WT and FUS454-526 P525L in a new supplementary figure (new Fig. S1 ) and present all the Kds measured for the unmethylated FUS peptides/proteins in a schematic diagram (new Fig. 6D ). We also studied two new peptides that comprise the PY-NLS only and no RGG repeats (FUS504-526 WT and FUS504-526 P525L ). The comparison of all Kds obtained for the different peptides shows that especially the N-terminal residues of the RGG repeat region (454-488) have a strong contribution to TRN binding, since the presence of this sequence strongly enhances TRN binding, especially in the context of the P525L mutation, where it restores binding of the P525L mutant to wild-type levels (new Fig. 6D ).
The fact that methylation has a stronger effect in the context of the P525L mutation compared to the WT is supported by our pulldown assays ( Fig. 7B and C) , where methylation has a stronger effect on the P525L mutant peptides compared to the WT peptides.
3-Fig. 5: The data raise two obvious and related questions: First, if amino acids 514-526 are sufficient for nuclear import of FUS, independently of methylation, why is the RGG domain necessary? As the domain is present in three related proteins, it is probably there for a reason. Second, if arginine methylation in the RGG domain tends to inhibit nuclear import, what is the purpose of arginine methylation? In other words, having neither the arginine residues nor their methylation would seem more economical and more reliable with respect to nuclear import. These questions should be discussed.
The reviewer brings up some very interesting questions. As requested, we now discuss these points in our revised discussion (last paragraph). Fig. 7 Fig. 6D) . Second, FUS489-526 WT and FUS489-526 P525L were also compared side by side in a pulldown assay (see Fig. 7C right lane labeled P525L, this refers to the FUS489-526 P525L peptide). This also demonstrates a much better binding of the WT peptide compared to the P525L peptide. Only in the much longer FUS454-526 construct, which includes the entire RGG3 region, the WT and P525L mutant show equal TRN binding (Fig. 6D) , presumably due to the tight interaction of the RGG repeat region with TRN (Fig. 6C ).
4-
Minor points: p. 9, line 8: Cytosolic stress granules are visible in Fig. 4A , not B.
We corrected this mistake.
p. 9, line 10: The claim that GFP-M9M expression 'completely' blocked AdOx-induced nuclear import of FUS-P525L seems exaggerated -nuclear staining is still easily visible.
We rewrote this sentence.
Fig. 6 and corresponding text: It was not clear to me which tag was present on the two peptides (454 -526) used for NMR and ITC.
As stated in the supplementary material and methods (under "Recombinant protein expression and purification"), FUS454-526 WT and FUS454-526 P525L were purified as ZZ-His 6 -tagged fusion proteins and the tag was subsequently cleaved off and eliminated in a second affinity purification step, so untagged FUS454-526 proteins were used for NMR and ITC measurements.
Referee #3
Overall, I think this is a well written paper that takes the previously published evidence that inhibiting arginine methylation of ALS-causing FUS mutants can restore their nuclear import one step further, by indicating a mechanism by which this is likely to occur. Specifically the authors provide evidence indicating: 1)That this mechanism is transportin dependent; 2)That it requires the presence of the PY-NLS sequence of FUS; 3)That it also requires arginines in the RGG3 domain of FUS; 4)That the ALS-causing P525L mutation in the PY-NLS-sequence of FUS causes weaker binding of the mutant PY-NLS sequence to transportin and that when de-methylated, the RGG3 domain of FUS interacts tightly with TRN, thereby rescuing the weaker binding of the mutant PY-NLS sequence; 5)That Arginine methylation in the RGG3 domain of FUS impairs transportinbinding. On the basis of these novel findings, I conclude that this paper should be accepted, providing the following amendments are made:
Specific points:
1 -In the authors previous Embo publication (Dormann et al., 2010) We apologize for omitting the information that pictures and quantification shown are from one experiment, but are representative of at least three independent experiments. We now state this in the materials and methods (under "Fluorescence image acquisition" and "Image quantification and statistics").
2-There appears to be a mistake on page 16 in the following sentence: "Indeed, a recent study reported that arginine methylation of the nuclear poly(A) binding protein (PABPN1) weakens its interaction with TRN and that several nuclear proteins, including FUS, show reduced TRN binding in PRMT1 knockout cells (Fronz et al., 2011) As explained under specific point 2 of reviewer 1, we have used novel meFUS-specific monoclonal antibodies to show that both FUS-WT and ALS-associated FUS mutants are methylated (new Fig. 8 ) and that inclusions in ALS-FUS patients contain methylated FUS, while inclusions in FTLD-FUS are unmethylated (new Fig. 9 ). Moreover, our in vitro pulldown experiments and ITC data clearly demonstrate that binding of FUS-WT to TRN is affected by arginine methylation (Fig.  7C) . Even though differences in TRN binding affinity of methylated versus unmethylated FUS-WT may be small, it seems possible that over long periods of time, a slight increase in FET-TRN binding may lead to a co-deposition of FET proteins and TRN in FTLD-FUS. Taken together, we now provide ample experimental evidence that arginine methylation may play a role in FTLD-FUS. Based on our new findings, we have substantially rewritten the paragraph referred to by the reviewer and now discuss the interesting differences in the neuropathology of ALS-FUS and FTLD-FUS and the idea that the two disorders may be caused by different pathomechanisms.
Additional Correspondence 17 August 2012
Thank you for submitting your revised manuscript to the EMBO Journal. Your revision has now been seen by referees #1 and 2. As you can see below, both referees appreciate the introduced changes and support publication here. I am therefore very pleased to proceed with the acceptance of the paper. I also would like to add that I appreciate very much the extra efforts that you undertook to address the concerns raised.
There are just a few formalities we need to take care of before the paper can be transferred to the publisher.
1) Referee #2 has a few minor text suggestions. You can send me a modified text by email address.
2) We also now encourage the publication of source data, particularly for electrophoretic gels and blots. Would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figure? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation could be useful but is not essential. The PDF files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this just contact me.
3) You have sent us the regular License to Publish (LTP) and the Page Charges Authorisation form already, but please read below regarding our EMBO Open Access option and in case that you might want to take it, please let us know within 48 hours and send us the related LTP. Please note that once your manuscript has been transferred to the publisher, no further changes can be made in this regard.
4) Please also note: A new policy at The EMBO Journal is for the transcript of the editorial process (containing referee reports and your response letter) to be published as an online supplement to each paper. If you do NOT want this in this case, you will need to inform the Editorial Office via email immediately (i.e. at the stage of providing licenses and/or confirming whether you take the EMBO OPEN option, see below).
EMBO OPEN OPTION Authors of accepted peer-reviewed original research articles may choose to pay a fee in order for their published article to be made freely accessible to all online immediately upon publication. The EMBO Open fee is fixed at $3,900 (+ VAT where applicable).
To take this option, please fill in the payment form (which can be accessed at this address http://mtsemboj.nature.com/letters/emboj_LTP_Open.pdf) and EMBO Open licence to publish form (http://mts-emboj.nature.com/letters/emboj_LTP_Open.pdf ) and return both to the editorial office within 48 hours. It is mandatory that the payment form be sent in along with the LTP. Failure to do so will result in your article being published as a standard paper behind access control.
For further information on EMBO Open, please use the link below to access our FAQs. http://www.nature.com/emboj/open_access_faqs.html Your manuscript will be processed by Nature Publishing Group for publication in the journal. Manuscripts in the printed and electronic editions of The EMBO Journal will be copy edited, and you will be provided with page proofs prior to publication. Please note that supplementary information is not included in the proofs.
If you have any questions, please do not hesitate to call or email us.
Yours sincerely Editor
The EMBO Journal REFEREE REPORTS Referee #1:
The authors have answered this reviewer's questions to complete satisfaction and should be commended for the additional work undertaken to perform this task at the experimental level.
Referee #2:
In the revision, the authors have taken care of my criticism. This is a good paper that should be published.
Before it goes to print, a few minor points can be taken care of: 
